非布司他治疗痛风疗效怎样呢？

Febuxostat is a drug used to treat gout. How effective is Febuxostat in treating gout?

Let’s follow the medical team to see the effect of febuxostat in the treatment of gout through two clinical trials.

A multicenter, double-blind, randomized phase II clinical study evaluated the safety and efficacy of febuxostat (febuxostat, feburic) in gout. A total of 136 male and 17 female gout patients were randomized to receive placebo or febuxostat (40, 80 or 120 mg/d). After 4 weeks, the test found that the serum uric acid concentration of patients in each dose group of febuxostat was significantly lower than before treatment, according to the dose from low to high. The average reductions in each group were 37%, 44% and 59% respectively, while patients in the placebo group only had a 2% reduction. The vast majority of patients persisted in completing the trial. Most of the adverse reactions of febuxostat were mild and self-limiting, with common ones including diarrhea, pain, back pain, headache and joint pain.

A phase III clinical trial compared the efficacy of febuxostat (80 and 120 mg/d) and allopurinol (300 mg/d) in parallel. A 1-year study of 760 patients showed that compared with the allopurinol group, more patients in the this product group achieved the main trial efficacy index - the sUA concentration was measured below 60 mg/L in the last 3 months (all subjects were gout patients, and the sUA concentration before the trial were all above 80 mg/L); after 52 weeks of treatment, this product failed to significantly reduce the area of tophi (pain). Tophi is an aggregate of urate crystals unique to gout), but in the high-dose group early in the trial, this effect was more obvious; in each treatment group, patients with sUA concentrations reaching the target were less likely to have gout attacks, and their tophi area was more significantly reduced; adverse reactions and their incidence were similar, including abnormal liver function, diarrhea, headache, joint-related signs and symptoms, and musculoskeletal/connective tissue symptoms.